Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

X
Trial Profile

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vebreltinib (Primary) ; Osimertinib
  • Indications Glioblastoma; Non-small cell lung cancer; Solid tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms SPARTA
  • Sponsors Apollomics
  • Most Recent Events

    • 28 Mar 2024 According to an Apollomics media release, the Company will continue enrollment in the SPARTA cohort to increase the precision around the point estimate for ORR and provide geographic diversity for the purpose of accelerated approval of an NDA to potentially support a marketing authorization. The company expect enrollment of these incremental patients in SPARTA will continue into 2025.
    • 28 Mar 2024 According to an Apollomics media release, if results from SPARTA and KUNPENG studies are positive, the Company could potentially submit an NDA in 2026 to seek accelerated approval.
    • 28 Mar 2024 According to an Apollomics media release, in Feb 2024, the Company had a productive meeting with the FDA on clinical data requirements for a potential NDA during which interim results from the SPARTA and KUNPENG studies were included and based on the meeting, the Company will continue to enroll in SPARTA cohorts and will review additional information on patients from both the trials with the FDA .
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top